WGS promises to offer a new level of personalized therapy, as illustrated here and in other cases such as the recent use of WGS to identify BCL2 inhibitors as a therapeutic option for a patient with chronic myeloid leukemia (CML) resistant to ponatinib therapy (Korfi et al. 2015). This evidence concerns the gene BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.